Oncology Innovation Symposium

6 & 7 juillet 2023

Corum de Montpellier

Sous l’égide du SIRIC Montpellier Cancer
Thursday 6th July, 2023

09h00 Welcome and opening remarks

- Marc Ychou, General Director of Montpellier Cancer Institute
- Nathalie Bonnefoy, Director of Montpellier Cancer Research Institute
- David Azria, Director of the SIRIC Montpellier Cancer

Day 1: Tumor Environment

SESSION 1

A complex and dynamic ecosystem
Chairman: Nathalie Bonnefoy

09h30 Leeat Keren, Weizmann Institute, Israel
Unraveling the tumor microenvironment by multiplexed imaging

10h00 Jean-Christophe Marine, VIB-KU, Leuven
Dissecting the melanoma ecosystem in space and time

10h30 Daniela Thommen, Netherlands Cancer Institute, Amsterdam
Spatio-temporal immune profiling and ICI response dynamics in human cancers

11h00 Coffee break (visit of the stands)

SESSION 2

Crosstalk between tumor cells and their microenvironment
Chairman: Guillaume Cartron

11h30 Antoine Italiano, Department of Medical Oncology, Bergonié Institute, Bordeaux
B Cells and Tertiary Lymphoid Structures: Biomarkers for Survival and Therapeutic Response of Cancer Patients

12h00 Fatima Mechtia-Grigoriou, Institut Curie, Paris
Role of fibroblast heterogeneity in immunosuppression and resistance to immunotherapy

12h30 Laetitia Linares, Institute of Cancer Research of Montpellier
A metabolic crosstalk between liposarcoma and muscle sustains tumor growth

13h00 Lunch

SESSION 3

Managing resistance to ICI: state of the art and what’s next?
Chairman: Nadine Houédé

14h30 Round table:
  - Philippe Bonnard, MSD
  - Antoine Adenis, ICM
  - Nathalie Bonnefoy, IRCM

17h00 End of the day
### Day 2: Therapeutic Innovation

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09h00</td>
<td>Opening conference</td>
</tr>
<tr>
<td></td>
<td>Bruno Quesnel, ITMO Cancer</td>
</tr>
</tbody>
</table>

#### SESSION 4

**AI for therapeutic Innovation**  
**Chairman: David Azria**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>09h30</td>
<td>Vassili Soumelis, Owkin company, Paris</td>
<td>Contribution of AI in oncology</td>
</tr>
<tr>
<td>10h00</td>
<td>Morgan Michalet, Montpellier Cancer Institute, Montpellier</td>
<td>Radiomics in radiation oncology</td>
</tr>
<tr>
<td>10h30</td>
<td>Nikos Paragios, Therapanacéa, Paris, Montpellier</td>
<td>AI applied to Radiotherapy</td>
</tr>
<tr>
<td>11h00</td>
<td>Michaël Delafosse, Mayor of Montpellier, President of Montpellier Méditerranée Métropole - MEDVALLÉE</td>
<td></td>
</tr>
<tr>
<td>11h15</td>
<td>Coffee break <em>(visit of the stands)</em></td>
<td></td>
</tr>
</tbody>
</table>

#### SESSION 5

**New paradigm in targeted therapy**  
**Chairman: Marc Ychou**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>11h30</td>
<td>Fabrice Barlesi, Gustave Roussy, Villejuif</td>
<td>Targeted therapies in Lung Cancer</td>
</tr>
<tr>
<td>12h00</td>
<td>Eric Van Cutsem, Leuven, Belgium</td>
<td>Targeted therapies in GI Cancer</td>
</tr>
<tr>
<td>12h30</td>
<td>William Jacot, Montpellier Cancer Institute, Montpellier</td>
<td>Monoclonal antibodies and ADCs in breast cancer</td>
</tr>
<tr>
<td>13h00</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>

#### SESSION 6

**From academic research to clinical application**  
**Chairman: Bruno Quesnel (ITMO CANCER)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14h30</td>
<td>Round table:</td>
</tr>
<tr>
<td></td>
<td>o Irène de La Porte, Astrazeneca</td>
</tr>
<tr>
<td></td>
<td>o Karine Chorro, Phost’in</td>
</tr>
<tr>
<td></td>
<td>o Mondher Mahjoubi, Innate Pharma</td>
</tr>
<tr>
<td></td>
<td>o Denis Fabre, OneHealth Partners</td>
</tr>
<tr>
<td>17h00</td>
<td>Conclusion of symposium</td>
</tr>
</tbody>
</table>
Thank you to our partners